NTX 1024
Alternative Names: NTX-1024Latest Information Update: 25 Apr 2023
At a glance
- Originator NexEos Bio
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Keratoconjunctivitis
Most Recent Events
- 17 Mar 2023 Preclinical trials in Keratoconjunctivitis in USA (Ophthalmic), prior to March 2023 (NexEos Bio pipeline, March 2023)
- 17 Mar 2023 Preclinical trials in Keratoconjunctivitis in USA (PO), prior to March 2023 (NexEos Bio pipeline, March 2023)